×
About 673 results

ALLMedicine™ Hypereosinophilic Syndrome Center

Research & Reviews  246 results

Myocarditis Pathology
http://emedicine.medscape.com/article/1612533-overview

Nov 5th, 2021 - Definition The term myocarditis refers to an inflammatory response within the myocardium that is not secondary to ischemic events or cardiac rejection in the setting of transplantation. The presence of myocyte necrosis is required for certain type...

Hypereosinophilia: a rare cause of stroke and multiorgan dysfunction.
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8488726
BMJ Case Reports; Barbind KL, Boddu R et. al.

Oct 3rd, 2021 - Eosinophilia can occur due to a plethora of allergic, infective, neoplastic and idiopathic conditions. Hypereosinophilic syndrome (HES) is characterised by sustained eosinophilia and multiorgan dysfunction in the absence of an identifiable cause. ...

MAP to Provide Access to Nilotinib, for Patients With HES
https://clinicaltrials.gov/ct2/show/NCT04498871

Sep 20th, 2021 - The purpose of this program is to allow access to nilotinib for eligible patients diagnosed with Hypereosinophilic syndrome (HES). The patient's Treating Physician should follow the suggested treatment guidelines and comply with all local health a...

Study to Evaluate Safety and Efficacy of Benralizumab in Subjects With Hypereosinophilic Syndrome
https://clinicaltrials.gov/ct2/show/NCT02130882

Sep 14th, 2021 - Hypereosinophilic syndrome (HES) is a rare group of heterogeneous disorders characterized by marked peripheral eosinophilia (>1500/(micro)L) and evidence of eosinophil-associated tissue damage. Although a high proportion of patients respond initia...

Recurrent prosthetic valve dysfunction in a patient with idiopathic hypereosinophilic s...
https://doi.org/10.1111/jocs.15927
Journal of Cardiac Surgery; Wei Z, Guo H et. al.

Aug 23rd, 2021 - Idiopathic hypereosinophilic syndrome with cardiac involvement is characterized by endocardial fibrosis and thrombosis. Here, we report a case of mitral valve prosthetic dysfunction in a patient with idiopathic hypereosinophilic syndrome and revie...

see more →

Drugs  6 results see all →

Clinicaltrials.gov  6 results

MAP to Provide Access to Nilotinib, for Patients With HES
https://clinicaltrials.gov/ct2/show/NCT04498871

Sep 20th, 2021 - The purpose of this program is to allow access to nilotinib for eligible patients diagnosed with Hypereosinophilic syndrome (HES). The patient's Treating Physician should follow the suggested treatment guidelines and comply with all local health a...

Study to Evaluate Safety and Efficacy of Benralizumab in Subjects With Hypereosinophilic Syndrome
https://clinicaltrials.gov/ct2/show/NCT02130882

Sep 14th, 2021 - Hypereosinophilic syndrome (HES) is a rare group of heterogeneous disorders characterized by marked peripheral eosinophilia (>1500/(micro)L) and evidence of eosinophil-associated tissue damage. Although a high proportion of patients respond initia...

Prospective Registry of Eosinophilia With Respiratory Manifestations With Translational Research Identifying and Characterizing Eosinophils
https://clinicaltrials.gov/ct2/show/NCT04538937

Sep 4th, 2020 - Introduction: The etiology and therapy of eosinophilic lung diseases are still poorly understood. For individual forms of disease, such as eosinophilic asthma or eosinophilic granulomatosis with polyangiitis (EGPA), new therapeutic approaches exis...

Natural History of Hypereosinophilia and Hypereosinophilic Syndromes
https://clinicaltrials.gov/ct2/show/NCT04018118

Aug 26th, 2020 - There is currently no data on the natural history of unexplained chronic hypereosinophilia (HE) and hypereosinophilic syndromes (HES). Clinical practice shows that HE/SHE patients can present 4 evolutionary profiles: A. a single flare-up of their ...

Identification of New Markers in the Hypereosinophilic Syndrome
https://clinicaltrials.gov/ct2/show/NCT01713504

Feb 15th, 2019 - The purpose is to characterize new hypereosinophilic syndrome biomarkers more informative and more accessible compared to those that we have already thanks to a proteomic approach. This will help the investigators to diagnose the this disease.

see more →

News  8 results

Next Generation of PDGFR Inhibitors Makes Headway in GIST
https://www.onclive.com/view/next-generation-of-pdgfr-inhibitors-makes-headway-in-gist

May 25th, 2021 - Dysregulated platelet-derived growth factor receptor (PDGFR) signaling is implicated in a number of cancer types and is among the targets of many FDA-approved multikinase inhibitors.1,2 Despite the success of these drugs in a range of malignancies...

Ex-FDA Chiefs Worry About COVID Vaccine Process; Doublespeak on Masks
https://www.medpagetoday.com/infectiousdisease/covid19/88934

Oct 2nd, 2020 - Seven former FDA commissioners from both parties penned an editorial criticizing the Trump administration for suggesting it could influence scientific standards for vaccine approval, potentially undermining public confidence in the agency's decisi...

FDA OKs Mepolizumab (Nucala) for Hypereosinophilic Syndrome
https://www.medscape.com/viewarticle/938221

Sep 28th, 2020 - The US Food and Drug Administration (FDA) has expanded the indication for mepolizumab (Nucala, GlaxoSmithKline) to include patients with hypereosinophilic syndrome (HES). Mepolizumab is indicated for adults and children aged 12 years and older wit...

FDA OKs Mepolizumab (Nucala) for Hypereosinophilic Syndrome
https://www.staging.medscape.com/viewarticle/938221

Sep 28th, 2020 - The US Food and Drug Administration (FDA) has expanded the indication for mepolizumab (Nucala, GlaxoSmithKline) to include patients with hypereosinophilic syndrome (HES). Mepolizumab is indicated for adults and children aged 12 years and older wit...

CHMP recommends approval of generic imatinib
https://www.mdedge.com/hematology-oncology/article/185423/cythemias/chmp-recommends-approval-generic-imatinib
HT Staff

Sep 18th, 2017 - Photo by Patrick Pelletier Imatinib tablet cut with a pill splitter The European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended granting marketing authorization for Imatinib Teva B. V.

see more →

Patient Education  3 results see all →